Skip to main content

 

 

ABROCITINIB Cibinqo® submission supporting PBS Listing for severe atopic dermatitis - 13 Sep 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme listing of ABROCITINIB Tablet 100 mg Tablet 200 mg Cibinqo® for severe atopic dermatitis.

pdfA&AA Abrocitinib Submission Sep 2021179.99 KB

 

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.

I understand More information